Evidence map›Paper›PMID 38385486›Full record

SynthesisCurrent pharmaceutical biotechnology2024

Anti-seizure Effects and Mechanisms of Berberine: A Systematic Review.

Nahid Jivad, Saeid Heidari-Soureshjani, Hesamaldin Bagheri, Catherine M T Sherwin, Sahar Rostamian

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Current pharmaceutical biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Nahid JivadDepartment of Neurology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.ORCID 0000-0001-6735-9577
Saeid Heidari-SoureshjaniModeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.ORCID 0000-0002-7592-3868
Hesamaldin BagheriMedical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.ORCID 0009-0007-8457-8633
Catherine M T SherwinProfessor and Vice-Chair for Research, Pediatric Clinical Pharmacology and Toxicology, Department of Pediatrics, Wright State University Boonshoft School of Medicine, Dayton Children's Hospital, One Children's Plaza, Dayton, Ohio, USA.ORCID 0000-0002-0844-3207
Sahar RostamianDepartment of Medicine, Harvard Medical School, Boston, USA.ORCID 0000-0003-4182-6004
Shahrekord University of Medical Sciences · IRBoston University · USWright State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpilepsy is one of the most common in all age groups and disabling neurologic disorders around the world.

objectivesThis systematic review was to explore whether berberine (BBR) has any anti-seizure or anti-epileptic effects and also reviewed this possible mechanism.

methodsThe EMBASE, Scopus, Cochrane Library, PubMed, and Web of Science databases were searched before Sep 2023. All types of studies that investigated the effects of BBR on epilepsy or chemical-induced seizures were eligible for inclusion. Two authors independently evaluated and reviewed titles/abstracts to identify publications for potential eligibility, and a third team member resolved discrepancies. Data were extracted in an Excel form, and the outcomes were discussed.

resultsBBR showed its neuroprotective properties by reducing oxidative stress, neuroinflammation, and anti-apoptosis effects. It also increases brain-derived neurotrophic factor (BDNF) release and reduces transforming growth factor-beta (TGF-β1) and hypoxia-inducible factor 1α (HIF-1α). BBR by increasing scavenging reactive oxygen species (ROS), nuclear factor erythroid 2-related factor 2 (Nrf2), endogenous antioxidant enzymes, heme oxygenase-1 (HO-1), and inhibition of lipid peroxidation insert its antioxidant activity. Moreover, BBR showed antiinflammatory activity by reducing Interleukin (IL)-1β, IL-6, and tumor necrosis factor-alpha (TNF-α) levels and through inhibiting cyclooxygenase-2 (COX-2), and including nuclear factor κB (NF-κB). In addition, it modulated c-fos expression and neuronal excitability in the brain.

conclusionBBR indicated promising anti-seizure effects with remarkable antioxidant, antiinflammatory, anti-apoptotic, and neuroprotective activity. Future studies should be based on well-designed clinical trial studies that are integrated with new methods related to increasing bioavailability.

Indexed as

BerberineAnimalsAnticonvulsantsAnti-Inflammatory AgentsAntioxidantsEpilepsyHumansNeuroprotective AgentsOxidative StressSeizuresAnticonvulsantsAnti-Inflammatory AgentsAntioxidantsBerberineNeuroprotective Agentsalkaloid.anticonvulsantanti-epilepticberberineEpilepsyseizure

Identifiers

PMID38385486
OpenAlexW4392049656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.